MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancerByoung Chul Cho, Alexander I. Spira, Shun Lü et al.|Future Oncology|2021Cited by 93
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAEnriqueta Felip, S.-H. Lee, Byoung Chul Cho et al.|Annals of Oncology|2024Cited by 81